Ventyx Biosciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $18.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Emily Bodnar has given her Buy rating due to a combination of factors, including the strategic adjustments Ventyx Biosciences has made in its ongoing Phase 2 trial of VTX2735 for recurrent pericarditis. The trial’s design has been modified to include a once-daily formulation and additional cohorts outside the US, which is expected to optimize the development timeline for Phase 3. These changes indicate Ventyx’s commitment to advancing the drug without a partner, showcasing confidence in their strategy.
Furthermore, the appointment of experienced advisors like Mark McKenna and Dr. Peter Libby to the strategic advisory board is seen as a positive step towards strengthening Ventyx’s 2026 strategy. The efficacy of rilonacept in similar trials serves as a benchmark for VTX2735, and the anticipated reductions in CRP and NRS scores bolster confidence in the drug’s potential. These elements combined suggest a promising outlook for Ventyx Biosciences, justifying the Buy rating.